Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic actinomycin D for high-risk complete hydatidiform mole.

S Limpongsanurak1

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

The Journal of Reproductive Medicine
|March 21, 2001
PubMed
Summary

Prophylactic actinomycin D significantly reduced malignant sequelae in high-risk complete hydatidiform mole (CHM) patients by 72.4%. This chemotherapy may benefit those with uncertain follow-up or unreliable hormonal monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of the Menopause-specific Quality of Life Scale for menopausal Thai women.

Climacteric : the journal of the International Menopause Society·2012
Same author

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

HIV medicine·2007
Same author

Pneumococcal vaccination during pregnancy for preventing infant infection.

The Cochrane database of systematic reviews·2006
Same author

Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy.

The Cochrane database of systematic reviews·2005
Same author

The international infections in pregnancy study: group B streptococcal colonization in pregnant women.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2004
Same author

Birthweight-specific neonatal mortality in developing countries and obstetric practices.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2003

Area of Science:

  • Gynecology
  • Oncology
  • Pharmacology

Background:

  • Complete hydatidiform mole (CHM) can progress to gestational trophoblastic neoplasia, necessitating chemotherapy.
  • High-risk CHM patients face a greater risk of malignant sequelae.
  • Prophylactic chemotherapy is explored to mitigate these risks.

Purpose of the Study:

  • To assess the efficacy of a single course of prophylactic actinomycin D in preventing chemotherapy-requiring malignant sequelae in high-risk CHM.
  • To quantify the risk reduction associated with this chemoprophylaxis.

Main Methods:

  • A double-blind, randomized controlled trial involving 60 high-risk CHM patients.
  • Patients were randomized to receive either actinomycin D chemoprophylaxis or a control (IV fluids and analgesics) within one week post-evacuation.

Related Experiment Videos

  • The primary outcome was the incidence of malignant sequelae requiring therapeutic chemotherapy.

    • Main Results:

    • The chemoprophylaxis group had a 13.8% incidence of malignant sequelae, compared to 50.0% in the control group.
    • Actinomycin D chemoprophylaxis resulted in a 72.4% risk reduction (P = .005).
    • Reported side effects included stomatitis, nausea/vomiting, sore throat with oral ulcer, and hair loss.

    Conclusions:

    • A single course of prophylactic actinomycin D effectively reduces malignant sequelae in high-risk CHM patients by 72.4%.
    • This approach is particularly valuable for patients with challenging follow-up compliance or unreliable hormonal monitoring.
    • Prophylactic actinomycin D offers a potential strategy to improve outcomes in high-risk CHM management.